Literature DB >> 7816196

Baroreceptor-aortic nerve-mediated release of endogenous L-3,4-dihydroxyphenylalanine and its tonic depressor function in the nucleus tractus solitarii of rats.

J L Yue1, H Okamura, Y Goshima, S Nakamura, M Geffard, Y Misu.   

Abstract

We have proposed that L-3,4-dihydroxyphenylalanine (L-DOPA) is a neurotransmitter and/or neuromodulator in the central nervous system [Misu Y. and Goshima Y. (1993) Trends pharmac. Sci. 14, 119-123]. This study aimed to explore whether or not endogenous L-DOPA, as a neurotransmitter candidate of the primary baroreceptor afferents, tonically functions to activate depressor neurons in the nucleus tractus solitarii of anesthetized rats. By parallel microdialysis in bilateral nucleus tractus solitarii areas, the basal L-DOPA release was in part inhibited by tetrodotoxin perfusion (1 microM) or Ca2+ deprivation, and was markedly reduced by alpha-methyl-p-tyrosine (200 mg/kg, i.p.), a tyrosine hydroxylase inhibitor. Forty to 100 mM K+ concentration-dependently released L-DOPA. Fifty millimoles K+ repetitively and constantly released L-DOPA. This release was Ca(2+)-dependent. Stimulation of the left aortic nerve (100 Hz, 8 V) repetitively and constantly released L-DOPA and this release was tetrodotoxin-sensitive. Phenylephrine i.v. infused produced L-DOPA release and reflex bradycardia, temporally associated with a rise and subsequent recovery of blood pressure. This release and bradycardia were abolished by denervation of the bilateral carotid sinus and aortic nerves. In addition, L-DOPA methyl ester, a competitive L-DOPA antagonist, when microinjected into depressor sites of the left nucleus tractus solitarii, antagonized depressor responses to mild stimulation (20 Hz, 3 V) of the ipsilateral aortic nerve. This antagonist alone, microinjected bilaterally, elicited a dose-dependent hypertension, which was abolished by alpha-methyl-p-tyrosine. Furthermore, by immunocytochemical analysis seven days after denervation of the left aortic nerve, tyrosine hydroxylase- and L-DOPA-, but not dopamine- and dopamine-beta-hydroxylase-immunoreactivities decreased in the ipsilateral nucleus tractus solitarii and dorsal motor vagus nucleus complex area. In the left ganglion nodosum, denervation decreased staining and number of L-DOPA-immunoreactive cells and staining of tyrosine hydroxylase-immunoreactive cells, but no modification of dopamine-immunoreactive cells was seen. Taken together with previous findings that L-DOPA itself is stereoselectively responsible for cardiovascular control in this nucleus, it is probable that L-DOPA is a neurotransmitter of the primary baroreceptor afferents terminating directly in depressor neurons and/or indirectly in some neurons within a microcircuit, including depressor neurons of the nucleus tractus solitarii. Endogenously released L-DOPA itself tonically functions to activate depressor neurons for regulation of blood pressure in the rat nucleus tractus solitarii.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7816196     DOI: 10.1016/0306-4522(94)90321-2

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  4 in total

1.  The protein Ocular albinism 1 is the orphan GPCR GPR143 and mediates depressor and bradycardic responses to DOPA in the nucleus tractus solitarii.

Authors:  Y Hiroshima; H Miyamoto; F Nakamura; D Masukawa; T Yamamoto; H Muraoka; M Kamiya; N Yamashita; T Suzuki; S Matsuzaki; I Endo; Y Goshima
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

2.  L-DOPA sensitizes vasomotor tone by modulating the vascular alpha1-adrenergic receptor.

Authors:  Daiki Masukawa; Motokazu Koga; Anna Sezaki; Yuka Nakao; Yuji Kamikubo; Tatsuo Hashimoto; Yuki Okuyama-Oki; Aderemi Caleb Aladeokin; Fumio Nakamura; Utako Yokoyama; Hiromichi Wakui; Hiroshi Ichinose; Takashi Sakurai; Satoshi Umemura; Koichi Tamura; Yoshihiro Ishikawa; Yoshio Goshima
Journal:  JCI Insight       Date:  2017-09-21

Review 3.  l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson's Disease.

Authors:  Yoshio Goshima; Daiki Masukawa; Yuka Kasahara; Tatsuo Hashimoto; Aderemi Caleb Aladeokin
Journal:  Front Pharmacol       Date:  2019-10-03       Impact factor: 5.810

Review 4.  The Many Faces of G Protein-Coupled Receptor 143, an Atypical Intracellular Receptor.

Authors:  Beatriz Bueschbell; Prashiela Manga; Anke C Schiedel
Journal:  Front Mol Biosci       Date:  2022-04-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.